Shanghai’s STAR rises as a destination for biotech IPOs

Shanghai’s STAR market could soon see a burst of biotech IPOs to rival the activity on HKEX

An analysis of recent and expected IPOs of Chinese biotechs suggests Shanghai’s STAR market could quickly catch up to, or even surpass, HKEX in the number of biotechs completing IPOs on the exchange.

Since Hong Kong

Read the full 361 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers